Table 3.

Summary of allele type effects of five candidate SNPs on lung cancer survival

Patient group (no. of cases)rs402710rs2736100rs4324798rs16969968rs8034191
HR (95% CI)PHR (95% CI)PHR (95% CI)PHR (95% CI)PHR (95% CI)P
All SCLC* (235)0.91 (0.71-1.17)0.4791.01 (0.81-1.25)0.9440.46 (0.30-0.73)0.0011.00 (0.79-1.26)0.991.02 (0.82-1.27)0.880
NSCLC ever smokers
    With surgery (849)1.05 (0.90-1.23)0.5220.91 (0.79-1.06)0.2271.18 (0.97-1.43)0.1020.93 (0.80-1.08)0.3360.91 (0.78-1.05)0.202
    No surgery (334)1.04 (0.87-1.25)0.6430.96 (0.80-1.14)0.6231.28 (0.93-1.76)0.1361.05 (0.88-1.25)0.5960.96 (0.80-1.15)0.663
NSCLC never smokers
    With surgery§ (211)1.16 (0.79-1.71)0.4481.21 (0.84-1.76)0.3111.12 (0.60-2.10)0.7301.26 (0.89-1.79)0.1861.15 (0.81-1.62)0.435
    No surgery§ (113)0.80 (0.56-1.14)0.2200.75 (0.54-1.04)0.0861.40 (0.79-2.46)0.2481.14 (0.84-1.55)0.4071.16 (0.86-1.58)0.332

Abbreviation: HR, hazard ratio.

  • *Adjusted for age at diagnosis, sex, smoking status, years quit smoking, stages of lung cancer, performance status, treatment modality, and disease progression/recurrence.

  • Adjusted for age at diagnosis, sex, history of COPD, smoking status, pack-year history of smoking, years quit smoking, stages and histologic types of lung cancer, treatment modality, and disease progression/recurrence.

  • Adjusted for age at diagnosis, sex, history of COPD, pack-year history of smoking, years quit smoking, stages and histologic types of lung cancer, treatment modality, and disease progression/recurrence.

  • §Adjusted for age at diagnosis, sex, second-hand smoke, stages and histologic types of lung cancer, treatment modality, and disease progression/recurrence.